Skip to main content
SpringerLink
Log in

Targeted therapies for RCC: high risk of MACE

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chen D-Y, et al. Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies JACC: CardioOncology : 19 Jul 2022. Available from: URL: https://doi.org/10.1016/j.jaccao.2022.05.002

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Targeted therapies for RCC: high risk of MACE. Reactions Weekly 1916, 11 (2022). https://doi.org/10.1007/s40278-022-19470-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-19470-x

Search

Navigation